Recce Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
RCE
- Share Price
-
$0.25
- (As of Monday Closing)
Recce Pharmaceuticals General Information
Description
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
Contact Information
Website
www.recce.com.auCorporate Office
- Level 15, 1 Farrer Place
- Governor Macquarie Tower
- Sydney, New South Wales 2000
- Australia
Corporate Office
- Level 15, 1 Farrer Place
- Governor Macquarie Tower
- Sydney, New South Wales 2000
- Australia
Recce Pharmaceuticals Timeline
Recce Pharmaceuticals Stock Performance
As of 16-Nov-2026, Recce Pharmaceuticals’s stock price is $0.25. Its current market cap is $76.7M with 306M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.25 | $0.25 | $0.18 - $0.49 | $76.7M | 306M | 260K |
Recce Pharmaceuticals Financials Summary
As of 30-Sep-2026, Recce Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 72,726 | 87,718 | 53,864 | 78,861 |
| EBITDA | (8,844) | (12,888) | (10,902) | |
| Net Income | (10,135) | (13,864) | (11,574) | |
| Total Assets | 5,869 | 8,109 | 4,257 | |
| Total Debt | 7,186 | 7,034 | 542 |
Recce Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Recce Pharmaceuticals Comparisons
Industry
Financing
Details
Recce Pharmaceuticals Competitors (25)
One of Recce Pharmaceuticals’s 25 competitors is Bristol-Myers Squibb, a Corporation company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden |
Recce Pharmaceuticals Patents
Recce Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025905142-A0 | Compounds and medical uses thereof | Pending | 29-Oct-2025 | ||
| AU-2020900270-A0 | Process for preparation of biologically active copolymer | Inactive | 31-Jan-2020 | ||
| AU-2021214418-A1 | Process for preparation of biologically active copolymer | Active | 31-Jan-2020 | ||
| AU-2021214418-B2 | Process for preparation of biologically active copolymer | Active | 31-Jan-2020 | ||
| CA-3166468-A1 | Process for preparation of biologically active copolymer | Active | 31-Jan-2020 | A61K31/765 |
Recce Pharmaceuticals Signals
Recce Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Recce Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Recce Pharmaceuticals FAQs
-
When was Recce Pharmaceuticals founded?
Recce Pharmaceuticals was founded in 2007.
-
Where is Recce Pharmaceuticals headquartered?
Recce Pharmaceuticals is headquartered in Sydney, Australia.
-
What is the size of Recce Pharmaceuticals?
Recce Pharmaceuticals has 15 total employees.
-
What industry is Recce Pharmaceuticals in?
Recce Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Recce Pharmaceuticals a private or public company?
Recce Pharmaceuticals is a Public company.
-
What is Recce Pharmaceuticals’s stock symbol?
The ticker symbol for Recce Pharmaceuticals is RCE.
-
What is the current stock price of Recce Pharmaceuticals?
As of 16-Nov-2026 the stock price of Recce Pharmaceuticals is $0.25.
-
What is the current market cap of Recce Pharmaceuticals?
The current market capitalization of Recce Pharmaceuticals is $76.7M.
-
Who are Recce Pharmaceuticals’s competitors?
Bristol-Myers Squibb, Merck & Co., Melinta Therapeutics, Gilead, and Gesynta Pharma are some of the 25 competitors of Recce Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process